Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04756726 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins, sponsored by C4 Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 224
- Enrollment target
- 13
- Study locations
NCT04756726: Active Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins, sponsored by C4 Therapeutics.
NCT04756726 is a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins that is active but no longer recruiting, run by C4 Therapeutics. The registered enrollment target is 224 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04756726, a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins, is active but no longer recruiting, sponsored by C4 Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 224 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Primary Outcome
Percent of subjects with adverse events (AEs) with cemsidomide as a single agent
Conditions Studied
Interventions
- DRUG Dexamethasone Oral
- DRUG cemsidomide
Study Locations (13)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Mt Sinai Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic - Phoenix
California
- University of California-San Francisco - San Francisco
Colorado
- Colorado Blood Cancer Institute (Sarah Cannon Research Institute) - Denver
Florida
- Mayo Clinic - Jacksonville
Georgia
- Emory University Hospital - Atlanta
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
What the registry record for NCT04756726 still lists
NCT04756726 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone Oral is the first listed.
NCT04756726 lists 13 locations in 11 states (Massachusetts, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT04756726 about?
NCT04756726 is a clinical study titled "Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma". The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma ...
What is the current status of trial NCT04756726?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2021-04-27. Estimated completion is 2026-03-31.
What conditions does trial NCT04756726 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkins.
What interventions are being tested in trial NCT04756726?
The interventions under investigation include: Dexamethasone Oral (DRUG), cemsidomide (DRUG).
Who is sponsoring clinical trial NCT04756726?
This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04756726 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04756726's enrollment target sits among peer trials
224 101st of 438 higher than 338 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI